Active Surveillance Saves more Costs than Administering Immediate Treatment for Prostate Cancer

July 17, 2012 by  
Filed under Prostate Cancer News

Active Surveillance is method of treatment for prostate cancer whereby medications are not applied. Instead, the progression and risk of the cancer is monitored for over some years.

This method works very well on men with low risk cancer of the prostate. A comparative study on the cost benefit between this approach and   the administration immediate treatment was made on recent study.

The findings of the study reveal that active surveillance in the long run do save money than immediate treatment. The result of the study was published in the July 2012 issue of “Cancer”. Below are more details on this   study:

 In a theoretical cohort of 120,000 men, selecting active surveillance for prostate cancer results in considerable cost savings at five and 10 years of follow-up, compared with immediate treatment, according to a study published in the July issue of Cancer.

To examine the health care costs of an active surveillance paradigm for prostate cancer, Kirk A. Keegan, M.D., from Vanderbilt University in Nashville, Tenn., and colleagues constructed a theoretical cohort of 120,000 men selecting active surveillance. A Markov model was used to simulate the number of men remaining on active surveillance and those exiting to each of five treatments over five years.

Estimated total costs of immediate treatment and delayed treatment after five and 10 years of active surveillance were compared. The researchers found that active surveillance with five years of follow-up and subsequent delayed treatment resulted in average cost savings of $16,042 per patient relative to initial curative treatment; this represented a saving of $1.9 billion dollars to the cohort.

In the ninth year of follow-up the strict costs of active surveillance exceeded those of brachytherapy. Compared with biopsy every other year, a yearly biopsy increased costs by 22 percent within the active surveillance cohort. Active surveillance still resulted in a cost benefit at 10 years of follow-up; however, the per patient savings were decreased by 38 percent (to $9,944) relative to initial treatment. “As the costs of health care rise, through the utilization of progressively more expensive technologies, the relative clinical and economic benefits of an active surveillance paradigm for the treatment of low-risk prostate cancer will likely become increasingly attractive,” the authors write. Source.

Logically, one will expect that when no treatment is administered for a disease, monetary cost is saved. This fact has been confirmed on the cohort study highlighted above.

However, there are still other costs associated with Active Surveillance, like the cost of undergoing the yearly biopsy which helps to determine the staging and possible risks posed prostate cancer.

That said, it is still good to know that active surveillance still provide more economic benefits than immediate treatment. This should help in proper decision making as the cost of health care rises.

Below Are Other Related Articles Among 1,000+ Prostate Cancer Articles On
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:

(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)


  1. Understanding Active Surveillance or Watchful Waiting in Prostate Cancer
  2. Robotic Prostate Cancer Surgery Too Costly than Open Surgery – Offers No Extraordinary Benefits
  3. Robotic-Assisted Laparoscopic Radical Prostatectomy (RARP) Costlier than Radical Retropubic Prostatectomy (RRP)

Speak Your Mind

Tell us what you're thinking... !

s